Professori L.A. Puntila 17/3 1961

Kirje 17.3.1961

Radiopuhe 17.3.1955

Puhe

Professori Kustaa Vilkuna 17/3 1965

Kirje 17.3.1965

Iowa Developments, May 2008, Volume 17, Number 3

Business News from the Iowa Department of Economic Development

Iowa Growers' News, November 17, 2008, Issue 3

Newsletter produced by Iowa Department of Agriculture and Land Stewardship for Iowa Growers.

Secure and Prepared Newsletter, October 2, 2007, Vol. 3, no. 17

A bi-weekly newsletter for those involved in the fields of homeland security and/or emergency management

The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine.

The selective serotonin reuptake inhibitor fluoxetine is administered as a racemic mixture, and R- and S-fluoxetine are metabolized in the liver by N-demethylation to R- and S-norfluoxetine, respectively. R- and S-fluoxetine and S-norfluoxetine are equally potent selective serotonin reuptake inhibitors, but R-norfluoxetine is 20-fold less potent in this regard. Racemic fluoxetine and norfluoxetine are potent inhibitors of cytochrome P450 (CYP) 2D6 in vivo and in vitro and recent studies in vivo have shown that racemic fluoxetine is metabolized by CYP2D6. The primary aim of the present study was to investigate the stereoselective metabolism of fluoxetine and norfluoxetine by CYP2D6 in vivo. A single oral dose of fluoxetine (60 mg) was administered to six poor and six extensive metabolizers of sparteine. Blood samples were collected during 6 weeks for poor metabolizers and 3 weeks for extensive metabolizers. Once a week a sparteine test was performed. The R- and S-enantiomers of fluoxetine and norfluoxetine were determined by a stereoselective gas chromatography-mass spectroscopy method. In the poor metabolizers, the oral clearance of R- and S-fluoxetine was 3.0 l/h and 17 l/h, respectively, the corresponding values in the extensive metabolizers were 36 l/h and 40 l/h, respectively. For both enantiomers, the phenotype difference was statistically significant. In poor metabolizers, the elimination half-lives were 6.9 days and 17.4 days for R- and S-norfluoxetine, respectively, and in the extensive metabolizers it was 5.5 days for both enantiomers, a significant phenotypical difference only for S-norfluoxetine. For fluoxetine the elimination half-lives were 9.5 and 6.1 days in poor metabolizers for the R- and S-enantiomer, respectively. The corresponding values in the extensive metabolizers were 2.6 and 1.1 days, respectively. Also for this parameter, the differences were statistically significant. This study shows that CYP2D6 catalyses the metabolism of R- and S-fluoxetine and most likely the further metabolism of S-norfluoxetine but not of R-norfluoxetine.

Business Sphere, Vol. 17, no.3

Through networking, Iowa’s manufacturers share expertise in lean manufacturing, supply chain efficiency and rapid prototyping, strengthening the powerful environment for success. The Iowa Department of Economic Development builds on these strengths with a focus on advanced manufacturing, extending financial and tax benefits to companies making substantial investments and creating higher skill, higher paying jobs. Many companies these days are finding that it pays to explore options in Iowa as they plan manufacturing expansions. You can get in touch with us at www.iowalifechanging.com.

Lottery Action Newsletter, February 8-21, 2010, Vol. 17, no. 3

Lottery Newsletter for Lottery Retailers

Lottery Action Newsletter, January 3-23, 2011 Vol. 17, no. 1

Lottery Newsletter for Lottery Retailers